MSI-1701 is primarily researched for its potential therapeutic applications, particularly in the field of oncology. It has shown promise as an anti-cancer agent, targeting specific pathways involved in tumor growth and proliferation. Studies suggest it may inhibit certain enzymes or proteins crucial for cancer cell survival, making it a candidate for developing targeted cancer therapies. Additionally, MSI-1701 is being explored for its role in modulating immune responses, which could enhance its efficacy in combination with immunotherapies. Its application is still largely in the preclinical or early clinical trial stages, with ongoing research to determine its safety, efficacy, and optimal use in treating various cancers.